- Email: [email protected]
Preparation of attenuated varicella vaccine by cultivation of the virus in a culture medium containing fowl embryo cells
Potent Report This section provides information on worldwide patents relevant to vaccine design and production. The Patent Report gives the following information: title of patent, patentee, patent number, publication and summary of the patent. A number of patents in this report are reproduced from 'Biotechnology Abstracts' with permission of Derwent Publications Ltd.
Inactivation of non-enveloped virus by contact cis-amine platinous halide and non-ionic detergent; vaccine production
Univ. California Eur 97-003:28 December 1983 Vaccine preparation comprises inactivation of a non-enveloped virus by contact with a cis-amine chelated platinous halide (A) and a small amount of a non-ionic detergent (B). A doublestranted D N A virus is used, e.g. an orbi virus, rota virus, picorna virus, reo virus, rhino virus or coxsackie virus, especially bluetongue virus. Preferably (A) is cis-diamine platinous chloride, and (B) is a (2-3C)alkytene. Highly effective vaccines are obtained, and the inactivation of the viruses is simple to effect, without the need for special equipment. Complete inactivation of the virions occurs, and they may be used directly and are acceptable to the host without causing significant detrimental effects. 045-84
Antigenic herpes simplex polypeptide produced by culturing cells transformed with a vector containing a viral DNA fragment
Behringwerke W. German 3228-501:2 February 1984 Polypeptide (A) is produced having an antigenic determinant of herpes simplex virus (HSV) and comprises isolating from the viral D N A a genome fragment coding for (At. This fragment is enzymatically attached to the D N A of a vector and the recombinant introduced into a cell able to express (A) which is then recovered. (A) Is useful in the production of antisera for detecting HSV,'or for preparation of vaccines. It can be used as a diagnostic reagent for detecting HSV antibodies. Viral D N A is recovered directly from the lysate of infected cells by centrifuging in a density gradient. It is then incubated with an endonuclease and the resulting fragments separated by agarose gel electrophoresis. The HindIII-K fragment is then ligated into the tetracycline gene of pBR322 and the resulting plasmid used to transform Escherichia coli HBI01. The transformants are selected on the basis of resistance to ampicillin and sensitivity to tetracycline, 048-84
Preparation of attenuated varicella vaccine by cultivation of the virus in a culture medium containing fowl embryo cells
Takeda Jpn unexamined 0058-220:21 May 1975
Novel DNA containing surface antigen and core antigen genes of hepatitis B virus; insertion in vector and expression in bacterial host; vaccine production
Takeda Jpn unexamined 8194-897:12 N o v e m b e r 1983 D N A containing hepatitis B virus surface antigen structural gene adw, surface antigen precursor gene and the core antigen structural gene is inserted into an expression vector, such as pBR322, downstream of a promoter. Bacterial hosts, such as Escherichia coli, are transformed with the vector to express the hepatitis B virus antigens. These antigens may be used in vaccine production. 046-84
Preparation of attenuated varicella vaccine comprises subjecting varicella virus to successive cultivation for three or more generations in a culture medium containing fowl embryo cells at the first generation. By using this method it is possible to obtain a vaccine which is attenuated and thus has no serious side effects in humans. It has high immunoactivity. The virus may be obtained by incubation of virus separated from the patient on a medium containing lung, kidney or other cells from a human, or it may be obtained by successive cultivation of the virus obtained as above. The embryo cells are obtained from a 7-11 day old chick which is free from RIF. The cultivation is conducted at 28-36°C, preferably at 29-34°C, for 5-17 days. The virus obtained is further cultivated in the medium followed by repetition of the process. The cultivation is conducted for more than five generations, but fewer than 25 generations. The attenuated virus is cultured in a medium containing cattle kidney cells etc. and the culture solution is subjected to purification. 049-84
Vaccine against bacteria containing capsular polysaccaride comprises oligosaccaride anchored in liposomes via lipophilic amine
Rijksuniv. Utrecht Eur 97-407; 4 January 1984 Vaccines against bacteria which include capsular polysaccarides contain oligosaccarides (O) anchored in a liposome via 14-22C alkylamine or other amine (e.g. phosphatidyl ethanolamines). (O) are derived from one or more pathogenic bacteria, especially Streptococcus pneumoniae. In this form. (O) are protected against in vivo decomposition and so provide better and longer-lasting immunity. Purified (O) from Strept. pneumoniae type III cells were dissolved in THF-water and stearylamine and NaCNBH3 were added. The mixture was reacted at room temperature for 10 days and evaporated to give crude glycolipids which were purified by dissolving in chloroform, mixing with water and recovering the intermediate layer from the emulsion. The glycolipids were dissolved in chloroform-methanol and the solution was mixed with dipalmitoyl-L-alphaphosphatidylcholine and cholesterol.The solvent was evaporated to form a thin film on the flask wall and saline was added. The flask was shaken at 61°C for l0 min, stood for I h and treated with ultrasound. 047-84
224
Vaccine, Vol. 2, September 1984
Preparation of attenuated varicella vaccine by cultivation of the virus in a medium containing cattle kidney cells
Takeda Jpn unexamined 0058-221:21 May 1975 Preparation of an attenuated varicella vaccine comprises subjecting varicella virus to successive cultivation for three or more generations in a culture medium containing cattle kidney cells, By using this method it is possible to obtain varicella vaccine which is attenuated and thus has no serious side effects in humans. It has a high immunoactivity, The virus may be one which is obtained by incubation of virus separated from a patient on a medium comprising lung, kidney or other cells, or one which is obtained by successive cultivation of'the virus obtained as above. The cultivation is conducted at 28-36°C, preferably at 29-34°C, for 5-17 days, with or without rotation. The virus obtained is further cultivated in the medium followed by repetition of the process. The cultivation is conducted for more than five generations but fewer than 25. The attenuated vaccine is incubated in a medium containing cattle kidney cells etc. and the culture solution is purified. 050-84
Inactivation of non-enveloped virus by contact cis-amine platinous halide and non-ionic detergent; vaccine production
Univ. California Eur 97-003:28 December 1983 Vaccine preparation comprises inactivation of a non-enveloped virus by contact with a cis-amine chelated platinous halide (A) and a small amount of a non-ionic detergent (B). A doublestranted D N A virus is used, e.g. an orbi virus, rota virus, picorna virus, reo virus, rhino virus or coxsackie virus, especially bluetongue virus. Preferably (A) is cis-diamine platinous chloride, and (B) is a (2-3C)alkytene. Highly effective vaccines are obtained, and the inactivation of the viruses is simple to effect, without the need for special equipment. Complete inactivation of the virions occurs, and they may be used directly and are acceptable to the host without causing significant detrimental effects. 045-84
Antigenic herpes simplex polypeptide produced by culturing cells transformed with a vector containing a viral DNA fragment
Behringwerke W. German 3228-501:2 February 1984 Polypeptide (A) is produced having an antigenic determinant of herpes simplex virus (HSV) and comprises isolating from the viral D N A a genome fragment coding for (At. This fragment is enzymatically attached to the D N A of a vector and the recombinant introduced into a cell able to express (A) which is then recovered. (A) Is useful in the production of antisera for detecting HSV,'or for preparation of vaccines. It can be used as a diagnostic reagent for detecting HSV antibodies. Viral D N A is recovered directly from the lysate of infected cells by centrifuging in a density gradient. It is then incubated with an endonuclease and the resulting fragments separated by agarose gel electrophoresis. The HindIII-K fragment is then ligated into the tetracycline gene of pBR322 and the resulting plasmid used to transform Escherichia coli HBI01. The transformants are selected on the basis of resistance to ampicillin and sensitivity to tetracycline, 048-84
Preparation of attenuated varicella vaccine by cultivation of the virus in a culture medium containing fowl embryo cells
Takeda Jpn unexamined 0058-220:21 May 1975
Novel DNA containing surface antigen and core antigen genes of hepatitis B virus; insertion in vector and expression in bacterial host; vaccine production
Takeda Jpn unexamined 8194-897:12 N o v e m b e r 1983 D N A containing hepatitis B virus surface antigen structural gene adw, surface antigen precursor gene and the core antigen structural gene is inserted into an expression vector, such as pBR322, downstream of a promoter. Bacterial hosts, such as Escherichia coli, are transformed with the vector to express the hepatitis B virus antigens. These antigens may be used in vaccine production. 046-84
Preparation of attenuated varicella vaccine comprises subjecting varicella virus to successive cultivation for three or more generations in a culture medium containing fowl embryo cells at the first generation. By using this method it is possible to obtain a vaccine which is attenuated and thus has no serious side effects in humans. It has high immunoactivity. The virus may be obtained by incubation of virus separated from the patient on a medium containing lung, kidney or other cells from a human, or it may be obtained by successive cultivation of the virus obtained as above. The embryo cells are obtained from a 7-11 day old chick which is free from RIF. The cultivation is conducted at 28-36°C, preferably at 29-34°C, for 5-17 days. The virus obtained is further cultivated in the medium followed by repetition of the process. The cultivation is conducted for more than five generations, but fewer than 25 generations. The attenuated virus is cultured in a medium containing cattle kidney cells etc. and the culture solution is subjected to purification. 049-84
Vaccine against bacteria containing capsular polysaccaride comprises oligosaccaride anchored in liposomes via lipophilic amine
Rijksuniv. Utrecht Eur 97-407; 4 January 1984 Vaccines against bacteria which include capsular polysaccarides contain oligosaccarides (O) anchored in a liposome via 14-22C alkylamine or other amine (e.g. phosphatidyl ethanolamines). (O) are derived from one or more pathogenic bacteria, especially Streptococcus pneumoniae. In this form. (O) are protected against in vivo decomposition and so provide better and longer-lasting immunity. Purified (O) from Strept. pneumoniae type III cells were dissolved in THF-water and stearylamine and NaCNBH3 were added. The mixture was reacted at room temperature for 10 days and evaporated to give crude glycolipids which were purified by dissolving in chloroform, mixing with water and recovering the intermediate layer from the emulsion. The glycolipids were dissolved in chloroform-methanol and the solution was mixed with dipalmitoyl-L-alphaphosphatidylcholine and cholesterol.The solvent was evaporated to form a thin film on the flask wall and saline was added. The flask was shaken at 61°C for l0 min, stood for I h and treated with ultrasound. 047-84
224
Vaccine, Vol. 2, September 1984
Preparation of attenuated varicella vaccine by cultivation of the virus in a medium containing cattle kidney cells
Takeda Jpn unexamined 0058-221:21 May 1975 Preparation of an attenuated varicella vaccine comprises subjecting varicella virus to successive cultivation for three or more generations in a culture medium containing cattle kidney cells, By using this method it is possible to obtain varicella vaccine which is attenuated and thus has no serious side effects in humans. It has a high immunoactivity, The virus may be one which is obtained by incubation of virus separated from a patient on a medium comprising lung, kidney or other cells, or one which is obtained by successive cultivation of'the virus obtained as above. The cultivation is conducted at 28-36°C, preferably at 29-34°C, for 5-17 days, with or without rotation. The virus obtained is further cultivated in the medium followed by repetition of the process. The cultivation is conducted for more than five generations but fewer than 25. The attenuated vaccine is incubated in a medium containing cattle kidney cells etc. and the culture solution is purified. 050-84